SEC Filings

Form S-1/A
VITAE PHARMACEUTICALS, INC filed this Form S-1/A on 09/08/2014
Document Outline
Entire Document (5558.6 KB)
Subdocument 1 - S-1/A - S-1/A
Page 1 - As filed with the Securities and Exchange Commission on September 8, 2014
Page 2 - Preliminary Prospectus
Page 3 - TABLE OF CONTENTS
Page 4 - PROSPECTUS SUMMARY
Page 5 - Our Most Advanced Product Candidates
Page 6 - VTP-37948
Page 7 - Our Collaborations
Page 8 - Our Strategy
Page 9 - Corporate Information
Page 10 - N/A
Page 11 - The Offering
Page 12 - N/A
Page 13 - SUMMARY FINANCIAL DATA
Page 14 - N/A
Page 15 - RISK FACTORS
Page 16 - We will require substantial additional financing to achieve our goals, and a failure to obtain this
Page 17 - Raising additional capital may cause dilution to our existing stockholders, restrict our operations
Page 18 - Our ability to use net operating loss and tax credit carryforwards and certain built-in losses to re
Page 19 - Risks Related to the Clinical Development and Regulatory Approval of Our Product Candidates
Page 20 - Clinical failure may occur at any stage of clinical development, and because our product candidates
Page 21 - If we or our partners fail to obtain regulatory approval in jurisdictions outside the United States,
Page 22 - We and BI rely on third parties to conduct preclinical studies and clinical trials for our product c
Page 23 - We intend to rely on third-party manufacturers, including BI with respect to VTP-34072 and VTP-37948
Page 24 - We may not be successful in establishing and maintaining additional strategic partnerships, which co
Page 25 - N/A
Page 26 - Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecut
Page 27 - Third-party claims of intellectual property infringement or misappropriation may prevent or delay ou
Page 28 - We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, wh
Page 29 - We may need to license certain intellectual property from third parties, and such licenses may not b
Page 30 - Our reliance on third parties requires us to share our trade secrets, which increases the possibilit
Page 31 - If we do not obtain protection under the Hatch-Waxman Amendments by extending the patent terms and o
Page 32 - Coverage and reimbursement may be limited or unavailable in certain market segments for our product
Page 33 - The impact of recent healthcare reform legislation and other changes in the healthcare industry and
Page 34 - We face substantial competition, which may result in others discovering, developing or commercializi
Page 35 - Our product candidates may cause undesirable side effects or have other properties that delay or pre
Page 36 - Risks Related to Our Business and Industry
Page 37 - Our employees, independent contractors, principal investigators, CROs, consultants, commercial partn
Page 38 - N/A
Page 39 - We may encounter difficulties in managing our growth and expanding our operations successfully.
Page 40 - If product liability lawsuits are brought against us, we may incur substantial liabilities and may b
Page 41 - Our internal computer systems, or those of our development partners, third-party clinical research o
Page 42 - Risks Related to Our Common Stock and this Offering
Page 43 - Our quarterly operating results may fluctuate significantly.
Page 44 - You will suffer immediate and substantial dilution in the net tangible book value of the common stoc
Page 45 - We do not intend to pay dividends on our common stock, and, consequently, your ability to achieve a
Page 46 - We are an emerging growth company, and the reduced reporting requirements applicable to emerging gro
Page 47 - Because a small number of our existing stockholders own a majority of our voting stock, your ability
Page 48 - N/A
Page 49 - INFORMATION REGARDING FORWARD-LOOKING STATEMENTS
Page 50 - INDUSTRY AND MARKET DATA
Page 51 - USE OF PROCEEDS
Page 52 - DIVIDEND POLICY
Page 53 - CAPITALIZATION
Page 54 - N/A
Page 55 - DILUTION
Page 56 - N/A
Page 57 - SELECTED FINANCIAL DATA
Page 58 - N/A
Page 59 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF
Page 60 - Strategic Partnerships
Page 61 - B-site Amyloid Precursor Protein-Cleaving Enzyme Inhibitors with BI
Page 62 - Financial Operations Overview
Page 63 - Milestone Revenue
Page 64 - N/A
Page 65 - RORgt
Page 66 - Contour and Technology Development
Page 67 - Revenue Recognition
Page 68 - Accrued Clinical and Preclinical Expenses
Page 69 - Stock-Based Compensation
Page 70 - Valuation of Privately-Held-Company Equity Securities Issued as Compensation
Page 71 - Results of Operations
Page 72 - General and Administrative.
Page 73 - General and Administrative.
Page 74 - Cash Flows
Page 75 - Comparison of Years Ended December 31, 2013 and 2012
Page 76 - Plan of Operation
Page 77 - Contractual Obligations and Commitments
Page 78 - Recently Adopted Accounting Standards
Page 79 - BUSINESS
Page 80 - N/A
Page 81 - in vivo
Page 82 - Our Strategy
Page 83 - Continue investing in technology, people and intellectual property.
Page 84 - Cortisol in Metabolic Disease
Page 85 - Market Opportunity
Page 86 - Preclinical Data
Page 87 - VTP-37948 Targeting b-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE) for Alzheimer's Diseas
Page 88 - BACE as a Target in Alzheimer's Disease
Page 89 - Market Opportunity
Page 90 - Figure 5: Rats brain tissue assayed for levels of Ab and concentrations of VTP-37948. The various sy
Page 91 - IL-17 and Th17 Cells in Autoimmunity
Page 92 - RORgt as a Target in Autoimmunity
Page 93 - Market Opportunity
Page 94 - Human Whole Blood Assay
Page 95 - Left
Page 96 - Development Plans
Page 97 - Inflammation in ACS
Page 98 - Market Opportunity
Page 99 - ABCA1 mRNA in Human Skin Fibroblasts
Page 100 - Figure 17: Cynomolgus monkeys were dosed once-a-day for 14 days with VTP-38443. Levels of mRNA for A
Page 101 - Development Plans
Page 102 - Figure 19: Depiction of the composition and architecture of the epidermis.
Page 103 - Preclinical Data
Page 104 - Figure 21: VTP-38543 induced genes critical for lipid transport and lipid synthesis in skin.
Page 105 - Inhibition of IL-6 Secretion by THP-1 Macrophages
Page 106 - Immuno-Oncology Program
Page 107 - Contour Discovery Process
Page 108 - de novo
Page 109 - Figure 27: Time to develop a novel chemistry solution and achieve animal proof-of-concept.
Page 110 - N/A
Page 111 - BACE
Page 112 - Intellectual Property
Page 113 - LXRb Acute Coronary Syndrome:
Page 114 - Manufacturing
Page 115 - Commercialization
Page 116 - Phase 1.
Page 117 - N/A
Page 118 - Post-approval Requirements
Page 119 - Regulation Outside of the United States
Page 120 - N/A
Page 121 - N/A
Page 122 - Coverage and Reimbursement
Page 123 - Employees
Page 124 - MANAGEMENT
Page 125 - Arthur Fratamico, R.Ph.
Page 126 - Charles W. Newhall, III
Page 127 - Board Composition
Page 128 - Director Independence
Page 129 - Compensation Committee
Page 130 - Director Compensation
Page 131 - N/A
Page 132 - EXECUTIVE COMPENSATION
Page 133 - Equity Compensation
Page 134 - Outstanding Equity Awards as of December 31, 2013
Page 135 - N/A
Page 136 - Severance Benefits
Page 137 - Retirement Benefits
Page 138 - Letter Agreement with New Chief Business Officer
Page 139 - Administration.
Page 140 - Corporate Transactions.
Page 141 - Changes in Capitalization.
Page 142 - Administration.
Page 143 - Changes in Capitalization.
Page 144 - Changes in Capitalization.
Page 145 - Administration.
Page 146 - 2014 Employee Stock Purchase Plan
Page 147 - CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Page 148 - Employment Agreements
Page 149 - N/A
Page 150 - PRINCIPAL STOCKHOLDERS
Page 151 - N/A
Page 152 - N/A
Page 153 - N/A
Page 154 - DESCRIPTION OF CAPITAL STOCK
Page 155 - Options
Page 156 - Anti-takeover Effects of Delaware Law and Our Restated Certificate of Incorporation and Bylaws
Page 157 - Limitation of Liability and Indemnification Matters
Page 158 - SHARES ELIGIBLE FOR FUTURE SALE
Page 159 - Rule 701
Page 160 - MATERIAL UNITED STATES TAX CONSIDERATIONS TO NON-U.S. HOLDERS
Page 161 - Distributions on Our Common Stock
Page 162 - U.S. Federal Estate Tax
Page 163 - N/A
Page 164 - UNDERWRITING
Page 165 - Commissions and Discounts
Page 166 - N/A
Page 167 - NASDAQ Market Listing
Page 168 - Discretionary Sales
Page 169 - Notice to Residents of the United Kingdom
Page 170 - Notice to Residents of the Netherlands
Page 171 - N/A
Page 172 - LEGAL MATTERS
Page 173 - VITAE PHARMACEUTICALS, INC.
Page 174 - Report of Independent Registered Public Accounting Firm
Page 175 - Balance Sheets
Page 176 - Statements of Operations
Page 177 - Statements of Comprehensive Income
Page 178 - Vitae Pharmaceuticals, Inc.
Page 179 - Statements of Cash Flows
Page 180 - 1. Organization
Page 181 - Notes to the Financial Statements (Continued)
Page 182 - Notes to the Financial Statements (Continued)
Page 183 - Notes to the Financial Statements (Continued)
Page 184 - Notes to the Financial Statements (Continued)
Page 185 - Notes to the Financial Statements (Continued)
Page 186 - Notes to the Financial Statements (Continued)
Page 187 - Notes to the Financial Statements (Continued)
Page 188 - Notes to the Financial Statements (Continued)
Page 189 - Notes to the Financial Statements (Continued)
Page 190 - Notes to the Financial Statements (Continued)
Page 191 - Notes to the Financial Statements (Continued)
Page 192 - Notes to the Financial Statements (Continued)
Page 193 - Notes to the Financial Statements (Continued)
Page 194 - Notes to the Financial Statements (Continued)
Page 195 - Notes to the Financial Statements (Continued)
Page 196 - Notes to the Financial Statements (Continued)
Page 197 - Notes to the Financial Statements (Continued)
Page 198 - Notes to the Financial Statements (Continued)
Page 199 - Notes to the Financial Statements (Continued)
Page 200 - Notes to the Financial Statements (Continued)
Page 201 - Notes to the Financial Statements (Continued)
Page 202 - Notes to the Financial Statements (Continued)
Page 203 - Notes to the Financial Statements (Continued)
Page 204 - Notes to the Financial Statements (Continued)
Page 205 - Notes to the Financial Statements (Continued)
Page 206 - Condensed Balance Sheets
Page 207 - Unaudited Condensed Statements of Operations
Page 208 - Unaudited Condensed Statements of Comprehensive Loss
Page 209 - Unaudited Condensed Statements of Cash Flows
Page 210 - Notes to Unaudited Condensed Financial Statements
Page 211 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 212 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 213 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 214 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 215 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 216 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 217 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 218 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 219 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 220 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 221 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 222 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 223 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 224 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 225 - Notes to Unaudited Condensed Financial Statements (Continued)
Page 226 - 5,000,000 Shares
Page 227 - PART II
Page 228 - Item 15. Recent Sales of Unregistered Securities
Page 229 - Item 16. Exhibits and Financial Statement Schedules
Page 230 - provided
Page 231 - SIGNATURES
Page 232 - N/A
Page 233 - EXHIBIT INDEX
Page 234 - N/A
Subdocument 2 - EX-1.1 - EX-1.1
Page 1 - Exhibit 1.1
Page 2 - Initial Registration Statement
Page 3 - Rules and Regulations
Page 4 - Material Adverse Effect
Page 5 - FINRA
Page 6 - Permits
Page 7 - Intellectual Property
Page 8 - environmental laws
Page 9 - ERISA
Page 10 - Money Laundering Laws
Page 11 - Written Testing-the-Waters Communication
Page 12 - Authorizations
Page 13 - N/A
Page 14 - N/A
Page 15 - Company Incentive Plans
Page 16 - Exhibit B
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - Exhibit A
Page 21 - N/A
Page 22 - N/A
Page 23 - Underwriter
Page 24 - N/A
Page 25 - N/A
Page 26 - N/A
Page 27 - N/A
Page 28 - SCHEDULE I
Page 29 - SCHEDULE II
Page 30 - Agreement
Page 31 - N/A
Page 32 - Sole Representative
Page 33 - EXHIBIT B
Subdocument 3 - EX-3.1 - EX-3.1
Page 1 - Exhibit 3.1
Page 2 - Delaware
Page 3 - CERTIFICATE OF INCORPORATION
Page 4 - N/A
Page 5 - [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
Page 6 - IN WITNESS WHEREOF,
Page 7 - ARTICLE II
Page 8 - Liquidation Preference
Page 9 - Redemption.
Page 10 - provided, however,
Page 11 - N/A
Page 12 - N/A
Page 13 - Other Conversion Price Adjustments, Stock Splits and Combinations.
Page 14 - Other Distributions.
Page 15 - No Fractional Shares and Certificate as to Adjustments.
Page 16 - provided
Page 17 - Voting Rights
Page 18 - ARTICLE X
Page 19 - N/A
Page 20 - CERTIFICATE OF OWNERSHIP AND MERGER
Page 21 - EXHIBIT A
Page 22 - Merger of Initio Pharmaceuticals, Inc., a Delaware Corporation, into Concurrent Pharmaceuticals, Inc
Page 23 - RESOLVED FURTHER,
Page 24 - ARTICLE II
Page 25 - Liquidation Preference
Page 26 - N/A
Page 27 - Redemption
Page 28 - Conversion Price Adjustments for Certain Dilutive Issuances
Page 29 - N/A
Page 30 - N/A
Page 31 - Other Conversion Price Adjustments, Stock Splits and Combinations.
Page 32 - Recapitalizations
Page 33 - Protective Provisions
Page 34 - provided
Page 35 - ARTICLE V
Page 36 - ARTICLE X
Page 37 - RESTATED CERTIFICATE OF INCORPORATION
Page 38 - ARTICLE II
Page 39 - Liquidation Preference
Page 40 - N/A
Page 41 - Redemption
Page 42 - Conversion Price Adjustments for Certain Dilutive Issuances
Page 43 - N/A
Page 44 - N/A
Page 45 - Other Conversion Price Adjustments, Stock Splits and Combinations
Page 46 - Recapitalizations
Page 47 - Protective Provisions
Page 48 - provided
Page 49 - ARTICLE V
Page 50 - ARTICLE X
Page 51 - CERTIFICATE OF AMENDMENT
Page 52 - AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
Page 53 - ARTICLE II
Page 54 - Liquidation Preference.
Page 55 - N/A
Page 56 - N/A
Page 57 - Redemption.
Page 58 - Conversion Price Adjustments for Certain Dilutive Issuances
Page 59 - N/A
Page 60 - N/A
Page 61 - Other Conversion Price Adjustments, Stock Splits and Combinations
Page 62 - Notices
Page 63 - Protective Provisions
Page 64 - Status of Converted Stock
Page 65 - ARTICLE VI
Page 66 - ARTICLE XII
Page 67 - AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
Page 68 - ARTICLE II
Page 69 - Liquidation Preference
Page 70 - N/A
Page 71 - N/A
Page 72 - Redemption
Page 73 - Conversion Price Adjustments for Certain Dilutive Issuances
Page 74 - N/A
Page 75 - N/A
Page 76 - Other Conversion Price Adjustments, Stock Splits and Combinations
Page 77 - Notices
Page 78 - Protective Provisions
Page 79 - Status of Converted Stock
Page 80 - ARTICLE VI
Page 81 - ARTICLE XII
Page 82 - AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
Page 83 - ARTICLE II
Page 84 - Liquidation Preference
Page 85 - N/A
Page 86 - N/A
Page 87 - Redemption
Page 88 - Conversion Price Adjustments for Certain Dilutive Issuances
Page 89 - N/A
Page 90 - N/A
Page 91 - Other Conversion Price Adjustments, Stock Splits and Combinations.
Page 92 - Notices
Page 93 - Protective Provisions
Page 94 - provided
Page 95 - Voting Rights
Page 96 - ARTICLE X
Page 97 - N/A
Page 98 - CERTIFICATE OF AMENDMENT
Page 99 - [Remainder of Page Intentionally Left Blank]
Page 100 - AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
Page 101 - ARTICLE II
Page 102 - N/A
Page 103 - Liquidation Preference
Page 104 - N/A
Page 105 - Redemption
Page 106 - Mechanics of Conversion
Page 107 - Other Distributions
Page 108 - Reservation of Stock Issuable Upon Conversion
Page 109 - Voting Rights
Page 110 - Common Stock
Page 111 - ARTICLE VIII
Page 112 - ARTICLE XII
Page 113 - CERTIFICATE OF AMENDMENT
Page 114 - [Remainder of Page Intentionally Left Blank]
Page 115 - N/A
Page 116 - CERTIFICATE OF AMENDMENT
Page 117 - [Remainder of Page Intentionally Left Blank]
Page 118 - N/A
Page 119 - CERTIFICATE OF AMENDMENT
Page 120 - [Remainder of Page Intentionally Left Blank]
Page 121 - CERTIFICATE OF AMENDMENT TO THE
Page 122 - N/A
Page 123 - IN WITNESS WHEREOF
Subdocument 4 - EX-3.2 - EX-3.2
Page 1 - Exhibit 3.2
Page 2 - Common Stock
Page 3 - N/A
Page 4 - FIFTH
Page 5 - Removal
Page 6 - TENTH
Page 7 - TWELFTH
Page 8 - IN WITNESS WHEREOF, the undersigned has executed this Amended and Restated Certificate of Incorporat
Subdocument 5 - EX-4.1 - EX-4.1
Page 1 - Exhibit 4.1
Page 2 - COLUMBIA FINANCIAL PRINTING CORP. - www.stockinformation.com The following abbreviations, when used
Subdocument 6 - EX-5.1 - EX-5.1
Page 1 - Exhibit 5.1
Subdocument 7 - EX-10.5 - EX-10.5
Page 1 - Exhibit 10.5
Page 2 - VITAE PHARMACEUTICALS, INC.
Page 3 - ARTICLE 3. SHARES AVAILABLE FOR GRANTS
Page 4 - ARTICLE 4. ELIGIBILITY
Page 5 - N/A
Page 6 - ARTICLE 6. STOCK APPRECIATION RIGHTS
Page 7 - ARTICLE 7. RESTRICTED SHARES
Page 8 - ARTICLE 8. STOCK UNITS
Page 9 - ARTICLE 9. ADJUSTMENTS; DISSOLUTIONS AND LIQUIDATIONS; CORPORATE TRANSACTIONS
Page 10 - Spread
Page 11 - ARTICLE 12. TAXES
Page 12 - ARTICLE 13. FUTURE OF THE PLAN
Page 13 - ARTICLE 14. DEFINITIONS
Page 14 - Incumbent Board
Page 15 - IPO Date
Page 16 - Performance Period
Page 17 - Substitute Awards
Page 18 - APPENDIX A
Page 19 - To the extent that an Award is not intended to comply with Code Section 162(m), other measures of pe
Subdocument 8 - EX-10.29 - EX-10.29
Page 1 - Exhibit 10.29
Page 2 - VITAE PHARMACEUTICALS, INC.
Page 3 - Reorganizations
Page 4 - Statutory Plan
Page 5 - SECTION 5.
Page 6 - SECTION 6.
Page 7 - Unused Cash Balances
Page 8 - SECTION 10.
Page 9 - Committee s Discretion
Page 10 - SECTION 15.
Page 11 - IPO
Subdocument 9 - EX-10.30 - EX-10.30
Page 1 - Exhibit 10.30
Page 2 - TABLE OF CONTENTS
Page 3 - VITAE PHARMACEUTICALS, INC.
Page 4 - Employee
Page 5 - Termination of Employment
Page 6 - ARTICLE 4.
Page 7 - ARTICLE 6.
Page 8 - ARTICLE 8.
Page 9 - APPENDIX A
Subdocument 10 - EX-10.31 - EX-10.31
Page 1 - Exhibit 10.31
Page 2 - notwithstanding anything to the contrary in this letter agreement or in any document governing such
Subdocument 11 - EX-23.1 - EX-23.1
Page 1 - Exhibit 23.1
Page 2 - N/A